A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients
AP306 monotherapy significantly reduced serum phosphate levels and substantially improved the serum phosphate control rate in hemodialysis patients with hyperphosphatemia. AP306 was safe and well-tolerated.
Authors
- Pei Wang (ORCID: https://orcid.org/0000-0003-0895-6798)
- Guisen Li (ORCID: https://orcid.org/0000-0003-1970-9979)
- Menghua Chen (ORCID: https://orcid.org/0009-0004-5572-9162)
- Yingxue Cathy Liu
- Ming Shi
- Hongli Jiang (ORCID: https://orcid.org/0000-0001-9262-6112)
- Li Wang (ORCID: https://orcid.org/0000-0003-0510-7985)
- Ping Zhang (ORCID: https://orcid.org/0000-0001-6214-557X)
- Weifeng Zhang
- Yu Wang (ORCID: https://orcid.org/0000-0002-8683-6196)
- Li Zuo (ORCID: https://orcid.org/0000-0003-0553-0994)
- Qing Zhao (ORCID: https://orcid.org/0000-0003-2862-3886)
- Qun Luo (ORCID: https://orcid.org/0000-0001-7498-5883)
- Leyi Gu
- Kun‐Ling Ma
Institutions
- Nanchang University (CN)
- Shanghai Jiao Tong University (CN)
- Peking University (CN)
- Renji Hospital (CN)
- Peking University People's Hospital (CN)
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1016/j.ekir.2025.01.038
- Citations
- 4
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.72
Funders
- School of Medicine, Stanford University